Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierSpyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre’s pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Business segments
Q2 2022 · $1.3MThe company’s own SEC segment disclosure.
- Development Fee And Royalty$625.0K50%
- Development Fee$625.0K50%
For the full year FY2025, revenue was $0 and net income −$155M. Its largest product in 2022-Q2 was Development Fee And Royalty at $625K, 50.0% of the disclosed total, just ahead of Development Fee at 50.0%.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.